酪氨酸激酶抑制剂治疗期间发生甲状腺功能减退与非甲状腺癌晚期患者生存期延长相关
这项回顾性队列研究纳入2000至2017年三家附属学术医院中接受酪氨酸激酶抑制剂(TKI)治疗且有甲状腺功能检测的晚期非甲状腺癌成人患者,排除既往甲状腺疾病后共538例。TKI治疗期间亚临床甲状腺功能减退(SCH)72例(13%)、明显甲状腺功能减退(OH)144例(27%)。甲状腺功能减退患者总生存期(OS)显著延长,校正混杂因素后OH仍与OS显著相关(HR=0.561,p<0.0001),SCH未达显著(HR=0.796,p=0.165);作者认为TKI相关甲状腺功能减退不应导致TKI减量或停药。
要点
- TKI治疗期间SCH 72例(13%)、OH 144例(27%)。
- 甲状腺功能正常者中位OS 685天,SCH 1005天,OH 1643天(p<0.0001)。
- 校正后OH与OS显著相关(HR=0.561,p<0.0001),SCH未达显著(HR=0.796,p=0.165)。
核心结论
- TKI治疗期间新发甲状腺功能减退与晚期非甲状腺癌患者OS显著改善相关,不应因此导致TKI减量或停药,并可能提供独立预后信息。
研究设计与样本
- 回顾性队列研究,纳入2000至2017年三家附属学术医院中接受TKI治疗且有甲状腺功能检测的晚期非甲状腺癌成人患者,排除既往甲状腺疾病后共538例。
主要发现
- TKI治疗期间SCH 72例(13%),OH 144例(27%)。
- 中位OS:甲状腺功能正常者685天(CI 523-851),SCH 1005天(CI 634-1528),OH 1643天(CI 1215-1991),p<0.0001。
- 校正年龄、性别、种族/民族、癌症类型、癌症分期、ECOG体能状态和检查点抑制剂治疗后,OH仍与OS显著相关(HR=0.561,p<0.0001),SCH未达显著(HR=0.796,p=0.165)。
- 对TSH>5且<10 mIU/L的甲状腺功能减退患者(SCH和OH)按激素替代状态分层分析显示,激素替代与生存改善相关。
关键数值与推荐
- SCH定义:TSH 5-10 mIU/L,或游离甲状腺素正常时TSH更高;OH定义:TSH>10 mIU/L、游离甲状腺素低或需要替代治疗。
临床怎么用
- 作者认为TKI治疗期间新发甲状腺功能减退不应导致TKI减量或停药,并可能提供独立预后信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tyrosine kinase inhibitor (TKI)-induced thyroid dysfunction is recognized as a common adverse effect of treatment, but the importance of incident hypothyroidism during TKI therapy remains unclear. This study analyzed the prognostic significance of hypothyroidism during TKI therapy in cancer patients. METHODS: This was a retrospective cohort study of adult patients with advanced nonthyroidal cancer treated with TKI and available thyroid function testing at three affiliated academic hospitals from 2000 to 2017. Patients with preexisting thyroid disease were excluded. Demographic, clinical, and cancer treatment data were collected. Thyroid status with TKI treatment was determined from thyroid function testing and initiation of thyroid medication, and classified as euthyroid (thyrotropin [TSH] normal), subclinical hypothyroidism (SCH; TSH 5-10 mIU/L, or higher TSH if free thyroxine normal), or overt hypothyroidism (OH; TSH >10 mIU/L, low free thyroxine, or requiring replacement). Multivariate models were used to evaluate the effect of TKI-related hypothyroidism on overall survival (OS). RESULTS: Of 1120 initial patients, 538 remained after exclusion criteria. SCH occurred in 72 (13%) and OH in 144 (27%) patients with TKI therapy. Patients with hypothyroidism had significantly longer OS, with median OS in euthyroid patients of 685 days [confidence interval (CI) 523-851] compared to 1005 days [CI 634-1528] in SCH and 1643 days [CI 1215-1991] in OH patients (p < 0.0001). After adjustment for age, sex, race/ethnicity, cancer type, cancer stage, ECOG performance status, and checkpoint inhibitor therapy, OH remained significantly associated with OS (hazard ratio = 0.561; p < 0.0001), whereas SCH did not (hazard ratio = 0.796; p = 0.165). Analysis of hypothyroid patients (SCH and OH) with TSH >5 and <10 mIU/L stratified by hormone replacement status showed improved survival associated with hormone replacement. CONCLUSIONS: New hypothyroidism in cancer patients treated with TKI is associated with significantly improved OS, should not necessitate TKI dose reduction or discontinuation, and may provide independent prognostic information.
引用
- Lechner MG, Vyas CM, Hamnvik OR, et al. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. Thyroid. 2018. PMID: 29652597. doi:10.1089/thy.2017.0587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。